1008-00003 · Client 1008 · Memos & Analysis

internal-strategy-memo-termination.docx DOCUMENT Funds

17 / 35 ← → ✕

PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT WORK PRODUCT

MEMORANDUM

To: Patricia Dunmore, Partner, Calderwood & Harkness LLP

From: Omar Siddiqui, Associate, Calderwood & Harkness LLP

Date: October 16, 2023

Re: Lumos Analytics Inc. — Strategic Analysis of SAFE Termination Provisions, Refund Obligations, and Misrepresentation Exposure Following Vantage Peak Withdrawal Request

Matter No.: 1008-00003

Reviewed by: Patricia Dunmore

Right-click to update Table of Contents

I. Executive Summary

This memorandum analyzes the legal position and available strategic options for our client, Lumos Analytics Inc. ("Lumos" or the "Company"), following the October 15, 2023 request by Vantage Peak Ventures Fund II, L.P. ("Vantage Peak") for the return of its $3,500,000 investment under a Simple Agreement for Future Equity ("SAFE"), citing alleged material misrepresentation regarding the readiness of the Company's Prism Core v2.0 machine-learning compliance scoring module. This memorandum addresses the enforceability of the SAFE termination provisions, Lumos's refund obligations (both contractual and equitable), the Company's exposure to fraud and misrepresentation claims under Delaware law, and the recommended negotiation strategy for resolving this matter expeditiously and with minimal long-term damage to the Company.

The factual predicate for this crisis is as follows. On October 8, 2023, Peralta IP Consulting LLC ("Peralta"), a third-party validation consultant engaged by Lumos, completed functionality and accuracy validation testing of the Prism Core v2.0 machine-learning module. Peralta issued its report on October 9, 2023, revealing that the module achieved only 61% accuracy against a target benchmark of 92% — a shortfall of more than thirty percentage points that renders the product materially unfit for commercial deployment in its current state. On October 10, 2023, Lumos's Chief Technology Officer, Elliot Marsh, disclosed the validation failure to the Company's board of directors. The board convened a meeting on October 12, 2023, at which it determined that the failure constitutes a material product setback and debated the Company's disclosure obligations to its investors. On October 13, 2023, CEO Priya Narasimhan disclosed the setback to Vantage Peak's deal lead, Samantha Reyes. Two days later, on October 15, 2023, Vantage Peak communicated its request for the full return of its $3,500,000 SAFE investment, alleging that Lumos had made material misrepresentations regarding the readiness of Prism Core v2.0 in its August 2023 investor pitch materials.

It is anticipated that Lumos's co-investors in this financing round — Ridgeline Angel Fund, L.P. ("Ridgeline"), which funded $1,200,000 under a SAFE executed September 22, 2023, and Canopy Growth Capital LLC ("Canopy Growth"), which funded $1,100,000 under a SAFE executed September 29, 2023 — will follow Vantage Peak's lead and submit withdrawal requests in the near term. Additionally, Atlas Fintech Syndicate, L.P. ("Atlas Fintech"), which signed a term sheet on October 4, 2023 committing $1,000,000 but never executed a SAFE or transferred funds, is expected to withdraw from the round entirely. The total funded amount at risk is $5,800,000, representing the aggregate of all three executed and funded SAFEs ($3,500,000 + $1,200,000 + $1,100,000).

Based on the analysis that follows, our recommendation is that Lumos negotiate mutual termination of all three funded SAFEs with full refund of the aggregate $5,800,000 in purchase amounts, structured through Mutual Termination & Release Agreements that include broad mutual releases, covenants not to sue, no admission of liability by either party, mutual non-disparagement provisions, and robust confidentiality obligations. While Lumos has colorable defenses to both fraud and negligent misrepresentation claims — most notably the absence of scienter and the forward-looking nature of the "beta-ready by Q4 2023" representation — the risk/reward calculus decisively favors resolution. The litigation risk is meaningful, the reputational damage of a public dispute with a prominent venture fund would be severe, the funds have not been materially deployed and remain available for return, and the incremental costs of defense (legal fees, discovery burdens, management distraction) would be disproportionate to any conceivable benefit of resistance. Full refund, properly documented, is the cleanest path to preserving Lumos's viability and reputation for future fundraising efforts.

II. Factual Background

A. The SAFE Financing Round

Lumos Analytics Inc. is a Delaware C-corporation (EIN: 87-3491026; Delaware Secretary of State File No. 7394821), headquartered at 340 Folsom Street, Suite 1100, San Francisco, CA 94105. The Company is a seed-stage SaaS/fintech analytics company operating in the financial regulatory compliance and predictive risk scoring space. Lumos was incorporated in Delaware in 2021 and has maintained its principal place of business in San Francisco since inception.

In the summer of 2023, Lumos initiated a seed financing round with a total target of $6,800,000 in Post-Money SAFEs. The SAFEs were based on the Calderon Partners LLC ("YC") standard Post-Money SAFE form, with certain modifications negotiated with the lead investor's counsel. The terms of the round included a post-money valuation cap of $28,000,000 and no discount rate. The round was authorized by the Lumos board of directors via a written consent dated August 30, 2023, signed by all three directors: Priya Narasimhan (CEO and director), Elliot Marsh (CTO and director), and Kenji Watanabe (independent director and observer designee of Ridgeline Angel Fund from the pre-seed round).

The lead investor in the round was Vantage Peak Ventures Fund II, L.P., a Delaware limited partnership. Vantage Peak's general partner is Vantage Peak Capital Management LLC, whose managing partners are Catherine Aldridge and Raymond Petrov. The deal was sourced and led on the Vantage Peak side by Samantha Reyes, a principal at the firm. Vantage Peak committed $3,500,000 to the round. The SAFE between Lumos and Vantage Peak was executed on September 12, 2023, and funds in the amount of $3,500,000 were wired to Lumos's operating account at Silicon Valley Commerce Bank ("SVCB") (Account No. 8801-4427-3390) on the same date. In connection with the SAFE, Lumos and Vantage Peak executed a Pro Rata Rights Side Letter, also dated September 12, 2023, granting Vantage Peak certain participation rights in future equity financings.

Three co-investors participated in or committed to the round, with the following details:

• Ridgeline Angel Fund, L.P.: Ridgeline executed a SAFE for $1,200,000 on September 22, 2023. Funds were wired to the Lumos SVCB operating account on the same date. Ridgeline is also an existing pre-seed SAFE holder, having invested $500,000 under a SAFE with an $8,000,000 post-money valuation cap in August 2022. Ridgeline's pre-seed SAFE remains outstanding and is addressed separately in Section IX of this memorandum.

• Canopy Growth Capital LLC: Canopy Growth executed a SAFE for $1,100,000 on September 29, 2023. Funds were wired to the Lumos SVCB operating account on the same date.

• Atlas Fintech Syndicate, L.P.: Atlas Fintech committed $1,000,000 to the round and signed a non-binding term sheet on October 4, 2023. However, the SAFE was never executed, and no funds were transferred. Atlas Fintech's situation is addressed separately in Section VII.

All three executed SAFEs (Vantage Peak, Ridgeline, and Canopy Growth) were on identical substantive terms: a post-money valuation cap of $28,000,000, no discount, a most-favored-nation ("MFN") provision, and three conversion triggers — (i) an Equity Financing of at least $1,000,000 in aggregate new issuance, (ii) a Liquidity Event (defined to include a change of control, direct listing, or initial public offering), and (iii) a Dissolution Event. All three SAFEs are governed by Delaware law.

The total amount funded during the round was $5,800,000 ($3,500,000 from Vantage Peak + $1,200,000 from Ridgeline + $1,100,000 from Canopy Growth). The round remained open with respect to Atlas Fintech's $1,000,000 commitment, which would have brought the total to $6,800,000 against the round target.

B. The Product Setback — Prism Core v2.0

Lumos's core product, Lumos Prism, is an AI-driven financial analytics platform that provides real-time regulatory compliance dashboards and predictive risk scoring to mid-market financial institutions. The platform integrates with clients' existing data infrastructure to deliver automated compliance monitoring, anomaly detection, and risk assessment capabilities. As of July 2023, the platform generated monthly recurring revenue ("MRR") of approximately $38,000, derived from a growing but still modest customer base.

Prism Core v2.0 is the designation for the next-generation machine-learning compliance scoring module that Lumos has been developing as the centerpiece of its product roadmap. Prism Core v2.0 was intended to represent a significant advancement over the Company's existing compliance scoring capabilities by incorporating proprietary machine-learning algorithms designed to deliver substantially higher predictive accuracy and broader regulatory coverage. The technology underlying Prism Core v2.0 is the subject of U.S. Provisional Patent Application No. 63/987,214, filed on June 15, 2023, which covers the Prism Core predictive risk algorithm.

In the investor pitch materials circulated by Lumos to prospective investors in August 2023 — including the pitch deck, financial projections, and product roadmap summary — the Company represented Prism Core v2.0 as "beta-ready by Q4 2023." This representation was a central element of the investment thesis presented to Vantage Peak and the other round participants, as the commercial launch of Prism Core v2.0 was positioned as the primary near-term value creation event that would support the Company's $28,000,000 post-money valuation cap.

In order to validate the functionality and accuracy of the Prism Core v2.0 module, Lumos engaged Peralta IP Consulting LLC, a technology consulting firm led by Dr. Amir Farouk, to conduct independent third-party validation testing. Peralta completed its testing on October 8, 2023 and issued its final report on October 9, 2023. The report's findings were materially adverse: Prism Core v2.0 achieved only 61% accuracy against the 92% benchmark target that Lumos had established as the minimum threshold for commercial viability. This thirty-one-percentage-point shortfall represents a fundamental deficiency in the module's predictive capabilities and, in the assessment of CTO Elliot Marsh, would require an estimated four to six months of additional development work to remediate.

CTO Marsh disclosed the validation failure to the Lumos board of directors on October 10, 2023. The board convened a meeting on October 12, 2023, at which it formally determined that the Peralta validation failure constitutes a material product setback. The board also debated the Company's disclosure obligations under the information rights provisions negotiated into the SAFEs, as well as any general duties to update investors regarding material changes in circumstances. Following the board meeting and after consultation with this firm, CEO Priya Narasimhan notified Vantage Peak's deal lead, Samantha Reyes, of the product setback on October 13, 2023.

C. Vantage Peak's Response

On October 15, 2023 — two days after CEO Narasimhan's disclosure — Vantage Peak communicated its request for the return of the full $3,500,000 SAFE purchase amount. The request was made verbally by Samantha Reyes to Priya Narasimhan and was characterized as based on alleged material misrepresentation regarding product readiness. Vantage Peak has retained Whitfield Harte & Associates LLP as outside counsel in this matter. Whitfield Harte is a Palo Alto-based firm with offices at 3000 El Camino Real, Suite 500, Palo Alto, CA 94306. The lead partner on the matter is Jonathan Whitfield; the associate is Megan Trost. Whitfield Harte previously served as investor's counsel during the SAFE negotiation and provided the September 8, 2023 markup of the SAFE form, as well as subsequent revisions through September 11, 2023.

We anticipate receipt of a formal demand letter from Whitfield Harte imminently. As of the date of this memorandum (October 16, 2023), no formal written demand has been received, but based on the tone of the October 15 communication and the engagement of litigation-capable counsel, we expect a letter setting forth Vantage Peak's legal theories and demand within the next two to five business days. (Note: the formal demand letter was received on October 18, 2023, and will be addressed in a supplemental memorandum.)

D. Lumos's Financial Position

A clear understanding of Lumos's financial position is critical to evaluating the strategic options and the Company's capacity to fund either a refund or a litigation defense. As of the relevant dates, Lumos's financial position is as follows:

• Monthly recurring revenue: Approximately $38,000 as of July 2023.

• Monthly burn rate: Approximately $95,000, inclusive of payroll (14 full-time employees), office lease, cloud infrastructure costs, and general and administrative expenses.

• Pre-round cash position: Approximately $420,000 in the SVCB operating account prior to the receipt of round proceeds.

• Revolving credit line: $200,000 revolving line of credit at SVCB, with $0 drawn as of August 2023. The credit line remains available as of the date of this memorandum.

• Total funds received during the round: $5,800,000 (as detailed above).

• Current estimated cash position: Approximately $6,190,000, reflecting the pre-round cash position plus the $5,800,000 in round proceeds, less approximately $30,000 in net operating expenses and legal fees during the round period (September–October 2023), offset by revenue received during the same period.

• Post-full-refund cash position: If Lumos were required to return the full $5,800,000 in funded SAFE proceeds, the Company would be left with approximately $390,000 in operating cash.

• Post-refund runway: At the current monthly burn rate of approximately $95,000, a cash position of $390,000 would provide the Company with approximately 4.1 months of operating runway before exhausting available funds. This figure does not account for the undrawn $200,000 revolving credit line, which, if fully drawn, would extend the runway to approximately 6.2 months.

• Headcount: 14 full-time employees as of August 2023. Payroll is the largest component of the monthly burn rate.

The critical takeaway from this financial analysis is that Lumos has not materially deployed the SAFE proceeds. The $5,800,000 in round funds remains substantially intact in the SVCB operating account and is available for return. This fact significantly simplifies the mechanics of a full refund and eliminates any argument that the Company lacks the capacity to make investors whole.

III. Analysis of SAFE Termination Provisions

A. Structure of the Post-Money SAFE

The SAFE instruments executed with Vantage Peak, Ridgeline, and Canopy Growth are based on the YC standard Post-Money SAFE form, with certain modifications negotiated during the September 2023 documentation process. As a threshold matter, it is important to understand the structural characteristics of the SAFE instrument that are relevant to the termination analysis.

A SAFE is not a debt instrument. It does not bear interest, does not have a maturity date, and does not impose any repayment obligation on the issuer. It is also not an equity security at the time of issuance — the SAFE holder does not receive shares of the company's stock and does not have voting rights, dividend rights, or other equity holder rights upon execution. Rather, a SAFE is a contractual right to future equity: the investor pays a purchase amount in exchange for the company's commitment to issue equity to the investor upon the occurrence of specified conversion events. The SAFE is, in essence, a contingent obligation that remains outstanding until triggered by a qualifying event.

The conversion triggers under the Lumos SAFEs are consistent with the standard YC form and include three events:

(1) Equity Financing: A bona fide transaction in which the Company issues and sells preferred stock in a new round of equity financing with aggregate new proceeds to the Company of at least $1,000,000.

(2) Liquidity Event: A change of control of the Company, a direct listing of the Company's securities on a public exchange, or an initial public offering.

(3) Dissolution Event: A voluntary termination of operations, a general assignment for the benefit of creditors, or any other liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary.

In the event of a Dissolution Event, the SAFE provides for the return of the purchase amount to SAFE holders (or a lesser pro rata amount from available assets) in priority to holders of common stock but junior to creditors. In all other respects, the SAFE does not contemplate or provide for a return of the purchase amount to the investor.

Critically, the standard YC SAFE form does not include any express termination-for-convenience provision. There is no mechanism by which either party may unilaterally terminate the instrument and trigger a return of funds outside of a Dissolution Event.

B. Absence of Contractual Termination Right

Having reviewed the executed SAFE agreements in full, including the modifications negotiated by Whitfield Harte during the September 2023 documentation process, we confirm that none of the three executed SAFEs contains a unilateral investor termination or withdrawal provision. There is no "put" right, no "material adverse change" or "MAC" clause, and no other provision that would permit an investor to demand the return of its purchase amount based on adverse developments in the Company's business, product development, financial condition, or prospects.

This is consistent with the fundamental design of the SAFE instrument. The YC SAFE was intentionally structured to be irrevocable once executed and funded: the investor's capital is committed to the company, and the investor's return is entirely contingent on the occurrence of a conversion event. The investor bears the risk that no conversion event may ever occur and that the investment may be lost entirely — a feature that distinguishes the SAFE from a loan or other repayable instrument.

Accordingly, Vantage Peak does not have a contractual right under the terms of the SAFE to compel the return of its $3,500,000 purchase amount. The same analysis applies with equal force to the Ridgeline SAFE ($1,200,000) and the Canopy Growth SAFE ($1,100,000). The investors' only contractual path to recovery of their purchase amounts would be through a Dissolution Event (in which case the amounts would be returned only from available assets and subject to prior creditor claims) or through a negotiated mutual termination.

We note that Whitfield Harte, as experienced venture counsel, is undoubtedly aware of this structural reality. Vantage Peak's demand is therefore best understood not as an assertion of a contractual right but rather as a demand premised on extra-contractual legal theories (primarily fraud and misrepresentation) coupled with a practical expectation that Lumos will agree to a negotiated resolution to avoid the costs and risks of contested proceedings.

C. Mutual Termination as the Operative Path

While no party has a unilateral right to terminate the SAFEs, both parties retain the ability to agree to terminate the instruments by mutual written consent. Mutual termination is the operative legal mechanism through which a refund can be effectuated in an orderly and documented manner.

A mutual termination would require the negotiation and execution of a definitive agreement addressing several key matters:

(i) The refund amount and payment timing;

(ii) Broad mutual releases of all claims arising out of or related to the SAFE, the financing round, and the circumstances giving rise to the termination;

(iii) Continuing confidentiality obligations of both parties with respect to non-public information exchanged during the investment process and the terms of the termination itself;

(iv) Treatment of any proprietary information, intellectual property, or trade secrets shared with the investor during the due diligence process;

(v) Termination of any ancillary agreements (such as the Pro Rata Rights Side Letter with Vantage Peak);

(vi) Representations regarding the absence of liens, encumbrances, or third-party claims on the SAFE or the refund proceeds; and

(vii) Appropriate no-admission-of-liability language and mutual non-disparagement covenants.

We recommend structuring these agreements as "Mutual Termination & Release Agreements," with separate agreements for each of the three funded investors. The use of separate agreements allows for customization where necessary — most importantly, the Ridgeline agreement must include a carve-out preserving Ridgeline's pre-seed SAFE, as discussed further in Section VIII below.

D. Impact of Dissolution Event Provisions

As noted above, in the event of a Dissolution Event, the SAFE provides for return of the purchase amount (or a lesser pro rata amount from available assets) to SAFE holders in priority to common stockholders but junior to creditors. While a Dissolution Event is not currently applicable, this provision is relevant to the broader strategic analysis for two reasons.

First, the limited runway available to Lumos post-refund (approximately 4.1 months at current burn rates) raises the realistic possibility that the Company could face a Dissolution Event in the first half of 2024 if it is unable to secure alternative financing. If that were to occur while the SAFEs remain outstanding (i.e., if Lumos refuses to refund and the SAFEs are not terminated), the investors would be entitled to return of their purchase amounts from available assets under the Dissolution Event provisions — but only to the extent funds are available at that point, which could be substantially less than the full purchase amounts given ongoing cash consumption. This dynamic actually strengthens the case for a prompt full refund while the funds are still available, rather than risking a scenario in which the Company's assets are depleted and investors recover only a fraction of their investment.

Second, the Dissolution Event provision underscores the SAFE's structural bias toward investor recovery in downside scenarios. Vantage Peak and the co-investors are acutely aware that their best path to full recovery is a negotiated refund while the Company remains solvent and the funds are intact.

IV. Contractual and Equitable Refund Obligations

A. Contractual Basis for Refund

As established in Section III above, no express refund obligation exists under the terms of the executed SAFEs outside of a Dissolution Event. The SAFEs do not contain any provision entitling an investor to demand return of the purchase amount based on product setbacks, failure to meet development milestones, material adverse changes in the Company's business, or any other adverse event short of dissolution. The instruments are, by their terms, irrevocable commitments of capital in exchange for contingent equity rights.

Vantage Peak's refund request is therefore not grounded in any contractual right under the SAFE itself. Rather, it is premised on an extra-contractual theory: that the SAFE was procured through material misrepresentation regarding the readiness of Prism Core v2.0, and that this misrepresentation vitiates Vantage Peak's consent to the instrument, rendering it voidable at the investor's election. This theory sounds in tort and equity rather than in contract, and the appropriate remedy — if the theory were sustained — would be equitable rescission, not contractual damages.

B. Equitable Rescission

Under Delaware law, a contract procured by fraud or material misrepresentation may be rescinded at the election of the injured party. Rescission is an equitable remedy that returns the parties to the status quo ante — that is, the position they occupied before the transaction. In the context of a SAFE, rescission would require Lumos to return the $3,500,000 purchase amount to Vantage Peak, and Vantage Peak would surrender its SAFE and all rights thereunder.

The elements for equitable rescission based on misrepresentation under Delaware law are as follows:

(1) A false representation of a material fact;

(2) Knowledge of the falsity of the representation or reckless disregard for its truth or falsity (in the case of fraud), or lack of reasonable grounds for believing the representation to be true (in the case of negligent misrepresentation);

(3) An intent to induce the other party to act in reliance upon the representation;

(4) Justifiable reliance by the other party upon the representation; and

(5) Resulting damage or prejudice to the other party.

If a court were to find these elements satisfied and order rescission, Lumos would be required to return the full purchase amount, and could additionally be liable for prejudgment interest, reasonable attorneys' fees in appropriate circumstances, and costs. The potential for these incremental liabilities is a further consideration weighing in favor of a voluntary resolution.

Equitable rescission is a particularly attractive remedy for Vantage Peak in this context because the SAFE has not yet converted to equity. There are no realized gains or losses, no dividends, and no other equity-related benefits that would complicate the unwinding of the transaction. The remedy of rescission here is, as a practical matter, simply a return of cash — making it straightforward to implement and easy for a court to order.

C. Restitution and Unjust Enrichment

As an alternative or supplementary equitable theory, Vantage Peak could seek restitution of the $3,500,000 under principles of unjust enrichment. Under this theory, if the SAFE were deemed void ab initio (i.e., void from its inception due to a fundamental defect in formation, such as fraud), Lumos's retention of the purchase amount would constitute unjust enrichment because there would be no valid contractual basis for the Company's receipt and retention of the funds.

Lumos's principal defense to an unjust enrichment claim would be that the SAFE is a valid and enforceable contract, and that funds received pursuant to a valid contractual obligation cannot give rise to an unjust enrichment claim. This defense is generally sound under Delaware law, which recognizes that unjust enrichment claims are precluded where a valid contract governs the subject matter of the dispute. However, this defense is circular in the present context: if the SAFE is voidable due to fraud, the contractual defense to unjust enrichment falls away.

As a practical matter, the unjust enrichment theory adds little to Vantage Peak's position beyond what is already available through rescission, but it provides an alternative legal basis and could be pled in the alternative if litigation were to ensue.

D. Practical Considerations

Several practical considerations bear on the refund analysis and support the recommendation of full refund:

Availability of funds. As noted in Section II.D, the $5,800,000 in aggregate SAFE proceeds has not been materially deployed. The funds remain substantially intact in the Lumos SVCB operating account and are readily available for return. This eliminates any argument that Lumos lacks the financial capacity to make investors whole and removes a potential source of dispute regarding the mechanics of refund.

Partial refund or negotiated haircut. It is theoretically possible that Lumos could attempt to negotiate a partial refund — retaining a portion of the funds to cover administrative costs, legal fees, or other expenses incurred in connection with the round. However, this approach is strongly inadvisable for several reasons. First, the amounts at issue (likely in the range of $50,000–$100,000 in incremental costs) are trivial relative to the $5,800,000 total, and insisting on a haircut would signal bad faith and likely escalate the dispute. Second, any deduction from the refund amount would need to be justified and documented, creating additional points of contention. Third, Vantage Peak's counsel at Whitfield Harte would almost certainly reject a partial refund and treat it as an occasion to escalate to formal litigation. The marginal benefit of retaining a small portion of the funds is far outweighed by the risk of escalation.

Reputational preservation. A full and prompt refund, accompanied by appropriate documentation and mutual releases, sends a signal to the market that Lumos is acting with integrity and professionalism in the face of a product setback. This is the single most important consideration for a seed-stage company that will need to return to the capital markets in the near term.

Based on the foregoing, we recommend that Lumos agree to a full refund of the $5,800,000 in aggregate SAFE purchase amounts as the centerpiece of the resolution strategy.

V. Fraud and Misrepresentation Exposure Under Delaware Law

A. The Alleged Misrepresentation

The core factual predicate for Vantage Peak's misrepresentation claim is the representation made in Lumos's August 2023 investor pitch materials that Prism Core v2.0 would be "beta-ready by Q4 2023." This representation appeared in the product roadmap section of the pitch deck that was circulated to Vantage Peak and other prospective investors during the fundraising process, and it was reiterated verbally by CEO Narasimhan and CTO Marsh during investor meetings in August and early September 2023.

At the time this representation was made (August 2023), third-party validation testing by Peralta IP Consulting had not yet been conducted. Peralta was engaged to validate the functionality and accuracy of the module, and its testing was not completed until October 8, 2023 — nearly two months after the pitch materials were circulated and approximately one month after Vantage Peak executed its SAFE on September 12, 2023.

When the Peralta report was issued on October 9, 2023, it revealed a fundamental shortfall: the Prism Core v2.0 module achieved only 61% accuracy against the 92% benchmark target that Lumos had established as the minimum threshold for commercial viability and beta deployment. CTO Marsh's assessment is that four to six months of additional development will be required to remediate the accuracy deficiency, meaning that a realistic beta-readiness date is now Q2 2024 at the earliest — a delay of at least one full quarter beyond the timeline represented to investors, and potentially two.

Vantage Peak's position, as communicated verbally by Samantha Reyes on October 15, 2023, is that the "beta-ready by Q4 2023" representation was materially false or misleading when made, and that the Company either knew or should have known that the product was not on track to meet this timeline. Vantage Peak asserts that it relied on this representation in deciding to invest $3,500,000 and would not have invested — or would have invested on materially different terms — had it known the true state of the product's development.

The key legal question is whether the "beta-ready by Q4 2023" statement constitutes a statement of present fact susceptible to a misrepresentation claim, or whether it is properly characterized as a forward-looking projection or expression of management's expectations — a category of statement that is generally more difficult to challenge as fraudulent or misleading. A secondary but important question is whether Lumos had a reasonable basis for the statement at the time it was made.

B. Common-Law Fraud (Delaware)

Under Delaware law, the elements of a common-law fraud claim are well established:

(1) A false representation of a material fact;

(2) Made with knowledge of its falsity or with reckless indifference to whether it is true or false (scienter);

(3) With the intent to induce the other party to act or refrain from acting;

(4) Reasonable reliance by the other party upon the representation; and

(5) Resulting damage.

We analyze each element below as applied to the facts at hand.

Falsity. The representation at issue — "beta-ready by Q4 2023" — is fundamentally a statement about the anticipated future state of a product under development. It is framed in forward-looking terms and relates to a timeline that had not yet arrived at the time the representation was made. Under Delaware law, statements regarding future events, predictions, and expectations are generally not actionable as fraud unless they are accompanied by a misrepresentation of present fact — for example, a false statement about the current state of development, the current results of testing, or the current probability of meeting a timeline. Lumos's strongest defense on this element is that the "beta-ready by Q4 2023" statement was a good-faith projection of the development timeline based on the information available to the CTO at the time, not a guarantee of a future outcome.

However, this defense is not airtight. If Vantage Peak can demonstrate that Lumos had internal data, testing results, or other information at the time of the August 2023 pitch that suggested the module was not on track to achieve the 92% accuracy benchmark by Q4 2023, the forward-looking characterization could be undermined. A statement of expectation is actionable if the speaker does not actually hold the stated expectation or has no reasonable basis for it. We have not yet had the opportunity to conduct a thorough review of the Company's internal development records, emails, and Brightmoor Data Systems for the June–August 2023 period, and we flag this as a critical area for factual investigation. If internal communications reveal that CTO Marsh or other members of the development team harbored doubts about the Q4 timeline prior to the pitch, Vantage Peak's case would be materially strengthened.

Materiality. Product readiness is unambiguously material to an investor's decision to invest in a seed-stage SaaS company whose principal value proposition is its technology platform. Lumos Prism is the Company's core product, and Prism Core v2.0 is the next-generation module that was positioned in the pitch as the primary near-term value driver. The Company's MRR of approximately $38,000 per month is insufficient to support its operations independently, making the successful commercialization of Prism Core v2.0 essential to the Company's growth trajectory and, ultimately, to the creation of investor value. The 61% vs. 92% accuracy gap is not a minor deviation from plan; it represents a fundamental deficiency that renders the module unfit for commercial deployment and requires months of additional development. Vantage Peak will have no difficulty establishing materiality.

Scienter. This is the most significant obstacle to Vantage Peak's fraud claim and the element on which Lumos's defense is strongest. Scienter requires proof that the defendant made the representation with knowledge of its falsity or with reckless disregard for whether it was true or false. At the time the pitch materials were circulated (August 2023) and the SAFE was executed (September 12, 2023), the Peralta third-party validation had not yet been conducted, and the validation failure was not discovered until October 8–9, 2023. CTO Marsh did not disclose the failure to the board until October 10, 2023, and there is no evidence presently known to us that any member of Lumos's management team was aware that the module would fail the accuracy benchmark at the time the "beta-ready by Q4 2023" representation was made.

That said, the scienter analysis is not entirely free from risk. Vantage Peak's counsel at Whitfield Harte may pursue several lines of argument:

(a) Internal testing conducted prior to the Peralta engagement may have revealed accuracy or performance concerns that were known to the development team but not disclosed to investors. If pre-Peralta testing data exists showing accuracy rates materially below the 92% target, this could establish that Lumos's management knew or should have known that the module was not on track for Q4 beta-readiness.

(b) CTO Marsh's four-to-six-month remediation estimate, rendered almost immediately after the Peralta report, may suggest that the nature of the deficiencies was already understood or foreseeable by the technical team, even if the precise accuracy figure was not known.

(c) The engagement of Peralta itself may be characterized as an acknowledgment by Lumos that the module's readiness was uncertain — if the Company had confidence in the product's accuracy, why was third-party validation deemed necessary before (rather than after) the stated beta launch?

While these arguments do not establish scienter on the current factual record, they create risks in discovery. A fraud claim would entitle Vantage Peak to broad discovery of Lumos's internal communications, development records, testing data, and project management files for the relevant period. If such discovery were to reveal unfavorable documents — even if not conclusive on scienter — the litigation dynamics would shift significantly in Vantage Peak's favor.

Reliance and Damages. Vantage Peak will argue that it relied on the "beta-ready by Q4 2023" representation in making its investment decision and that it suffered damage by deploying $3,500,000 in capital into a company with a materially different product trajectory than the one represented. Given that the product roadmap was a central feature of the pitch and the Q4 beta timeline was directly linked to the Company's growth projections and valuation, reliance is likely to be established. Damages in a rescission action are straightforward: the return of the $3,500,000 purchase amount.

Overall Assessment of Fraud Claim. Vantage Peak's common-law fraud claim faces significant hurdles on the scienter element based on the facts currently known to us. The forward-looking nature of the representation, the absence of knowledge of the validation failure at the time the SAFE was executed, and the inherent uncertainty of startup product development timelines all support Lumos's defense. However, the factual record is incomplete — particularly with respect to internal development data and communications — and discovery poses meaningful risks. We assess the probability of Vantage Peak prevailing on a fraud claim at approximately 25–35%, with the range depending heavily on what internal documents would reveal.

C. Negligent Misrepresentation

Negligent misrepresentation presents a more significant risk than common-law fraud because it requires a lower culpability threshold. The elements under Delaware law are:

(1) A misrepresentation of a material fact;

(2) Made without reasonable grounds for believing the statement to be true;

(3) With the intent to induce the other party to act in reliance upon the representation;

(4) Justifiable reliance by the other party; and

(5) Resulting damage.

The critical distinction from fraud is that negligent misrepresentation does not require proof of intentional deceit or reckless disregard for truth (scienter). Instead, it requires only that the defendant lacked reasonable grounds for believing the statement to be true — in other words, that the defendant was negligent in making the representation. This is a materially lower bar.

Applied to the present facts, the question becomes: did Lumos have a reasonable basis for representing Prism Core v2.0 as "beta-ready by Q4 2023" when the module had not yet undergone third-party validation and, as it turned out, was achieving only 61% accuracy against a 92% target? The thirty-one-percentage-point accuracy shortfall is not a marginal miss; it is a fundamental deficiency that suggests either (a) the module was at a much earlier stage of development than represented, or (b) the Company's internal assessment of the module's readiness was conducted without adequate rigor.

Vantage Peak will argue that a company representing a product as "beta-ready by Q4 2023" to prospective investors has an obligation to ensure that this representation is supported by credible internal data, and that circulating such a representation without first completing (or at least substantially completing) validation testing reflects a lack of reasonable care. The magnitude of the accuracy shortfall — 61% vs. 92% — may suggest that reasonable internal testing would have identified the risk of failure well before the pitch materials were circulated.

Lumos's defense to the negligent misrepresentation theory is that the "beta-ready by Q4 2023" representation reflected CTO Marsh's good-faith assessment of the development timeline based on internal progress metrics available at the time; that the validation failure was an unexpected and unforeseeable outcome that resulted from the complexity of the machine-learning algorithms rather than any deficiency in the development process; and that startup product development timelines are inherently uncertain, a reality that sophisticated venture investors such as Vantage Peak understand and accept. Lumos may further argue that the pitch deck's use of "beta-ready" language (as opposed to "commercially launched" or "fully validated") itself communicates that the product was not yet in final form and that further testing and iteration were anticipated.

These defenses have some merit, but they are weaker than Lumos's defenses to the fraud claim. The core problem is the magnitude of the shortfall. If the module had achieved 87% accuracy against a 92% target, the argument that the miss was unforeseeable and within the expected range of uncertainty would be far stronger. A 61% result suggests a more fundamental problem that may have been identifiable through internal testing. Moreover, the fact that Lumos chose to engage a third-party validator (Peralta) before the beta launch can be read as an implicit acknowledgment that the module's readiness was uncertain — which in turn undermines the argument that the "beta-ready by Q4 2023" representation was made on reasonable grounds.

Risk Assessment. We assess the probability of Vantage Peak prevailing on a negligent misrepresentation claim at approximately 40–55%. This represents a moderate-to-significant litigation risk, particularly because the claim is less dependent on discovering evidence of intentional misconduct and more focused on the reasonableness of the representation given the circumstances. The magnitude of the accuracy shortfall is a powerful fact that any factfinder would weigh heavily.

D. SAFE Contractual Defenses

Notwithstanding the analysis above, Lumos has several contractual defenses that may limit its exposure to misrepresentation claims:

Integration clause. The executed SAFEs contain an integration clause providing that the SAFE constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements, understandings, and representations, whether written or oral. Lumos could argue that any pre-contractual representations made in the pitch materials — including the "beta-ready by Q4 2023" statement — were superseded and extinguished by the executed SAFE, which does not contain any representation regarding product readiness, development timelines, or accuracy benchmarks.

This argument has some force, particularly with respect to negligent misrepresentation claims. Delaware courts have generally recognized that sophisticated parties who negotiate and execute integrated agreements may not later rely on pre-contractual representations that are not incorporated into the final agreement. However, this defense is subject to a critical limitation: Delaware courts have consistently held that integration clauses do not bar fraud claims based on extra-contractual representations, under the longstanding principle that a party cannot contractually insulate itself from its own fraud. See, e.g., RAA Mgmt., LLC v. Savage Sports Holdings, Inc., 45 A.3d 107 (Del. 2012); Abry Partners V, L.P. v. F & W Acquisition LLC, 891 A.2d 1032, 1058 (Del. Ch. 2006). This principle may extend to negligent misrepresentation in certain circumstances, though the case law is less developed on this point.

Absence of representations and warranties. The standard YC Post-Money SAFE does not include investor-protective representations and warranties from the issuer. Unlike a typical Series Seed or Series A stock purchase agreement — which typically contains detailed representations regarding the company's intellectual property, products, material contracts, compliance, litigation, and financial condition — the SAFE is a deliberately streamlined instrument that does not include these protections. The absence of a specific product-readiness warranty in the SAFE strengthens Lumos's argument that Vantage Peak did not bargain for, and was not entitled to rely upon, specific assurances regarding the state of Prism Core v2.0 development.

Limitations of liability and disclaimers. The standard YC SAFE form does not typically include limitation-of-liability or disclaimer provisions. We have reviewed the September 8 Whitfield Harte markup and the subsequent September 11 revised draft for any negotiated additions in this area. The modifications to the standard form were relatively limited and focused primarily on information rights, MFN mechanics, and minor definitional clarifications. No limitation-of-liability or disclaimer provisions were added. This means there is no contractual cap on damages or explicit disclaimer of extra-contractual representations that Lumos could invoke.

Overall assessment of contractual defenses. The integration clause and the absence of representations and warranties provide a useful defensive framework, particularly against negligent misrepresentation claims. However, these defenses are unlikely to bar a fraud claim entirely if Vantage Peak can establish the requisite elements, and they add complexity and cost to any litigation without guaranteeing a favorable outcome. The contractual defenses are best understood as tools for settlement leverage rather than as dispositive shields.

E. Duty to Update / Continuing Disclosure

A distinct but related area of exposure concerns Lumos's duty to update investors once the Prism Core v2.0 validation failure became known. Even if the initial "beta-ready by Q4 2023" representation was made in good faith and on reasonable grounds at the time (August 2023), Lumos may have had a duty to promptly correct or update that representation once the Peralta report revealed it to be inaccurate.

The SAFEs include information rights provisions that were negotiated during the documentation process with Whitfield Harte. The scope of these provisions — including any affirmative reporting obligations, notice requirements for material events, and timelines for communication — should be reviewed carefully against the actual course of events. We note that the September 8 Whitfield Harte markup and the September 11 revised draft introduced certain enhanced information rights provisions; the precise terms and their applicability to the present circumstances require close analysis and are addressed in greater detail in the separate Calderwood & Harkness memorandum on internal disclosure obligations dated October 12, 2023.

As a general matter under Delaware law, an issuer that learns of a material change in circumstances that renders prior representations misleading may have a duty to correct or update those representations, particularly where the prior representations were made in connection with a securities transaction and the transaction — or a related ongoing course of dealing — continues. Here, the SAFE financing round was still open at the time the Peralta report was issued: Atlas Fintech's $1,000,000 SAFE had not yet been executed, and the round had not formally closed. The fact that the transaction was ongoing may heighten Lumos's duty to disclose material developments to existing and prospective investors.

The timeline of Lumos's disclosure is as follows:

• October 8, 2023: Peralta completes validation testing.

• October 9, 2023: Peralta issues its report showing 61% accuracy.

• October 10, 2023: CTO Marsh discloses the failure to the board.

• October 12, 2023: Board meets, determines the failure is a material setback, and debates disclosure obligations.

• October 13, 2023: CEO Narasimhan discloses the setback to Vantage Peak's Samantha Reyes.

Lumos disclosed the product setback to Vantage Peak on October 13, 2023 — four days after the Peralta report was issued and three days after the board was informed. The question is whether this timing was sufficiently prompt. Four days is a relatively short period, particularly given the need for internal assessment, board deliberation, and legal consultation. However, Vantage Peak may argue that the delay — even if brief — prejudiced its ability to take protective action, or that the board's deliberation (including debate over whether to disclose at all) reflects a reluctance to be transparent rather than a good-faith process of evaluating the information.

On balance, the timing of disclosure is a secondary concern. The four-day window is defensible, and the fact that Lumos voluntarily disclosed the setback (rather than concealing it) is a significant point in the Company's favor. Nonetheless, any delay in disclosure is a factor that Vantage Peak's counsel will cite in support of the broader misrepresentation narrative, and it underscores the importance of resolving this matter promptly and cooperatively.

VI. Risk Assessment — Litigation Exposure

A. Probability of Litigation

If Lumos refuses to refund the SAFE purchase amounts or offers only a partial refund, the probability of formal litigation is high. Vantage Peak has already retained Whitfield Harte & Associates LLP, a firm with significant venture capital litigation experience, which signals a serious intent to pursue legal remedies if a negotiated resolution is not reached. The engagement of outside litigation counsel is not a step that a fund of Vantage Peak's stature takes lightly, and it should be interpreted as a credible indicator that Vantage Peak is prepared to file suit if necessary.

Moreover, if Vantage Peak initiates litigation, the co-investors — Ridgeline and Canopy Growth — would be expected to join the action or bring parallel claims. Both co-investors have the same set of facts, the same legal theories, and identical SAFEs. A joint action by all three investors would multiply Lumos's defense burden and create a unified front that would be difficult to resist.

Litigation would most likely be filed in the Delaware Court of Chancery or the Delaware Superior Court, consistent with the governing law provisions of the SAFEs. Both Lumos and the investor entities are Delaware entities, making Delaware the natural forum. The Delaware Court of Chancery, in particular, would have jurisdiction over the equitable rescission claims.

B. Potential Damages

If fraud or negligent misrepresentation were established in litigation, the primary remedy would be equitable rescission — return of the purchase amounts to the investors. Beyond the purchase amounts themselves, Lumos could face exposure to several categories of additional costs and damages:

(i) Prejudgment interest: Delaware courts routinely award prejudgment interest in rescission actions, typically at the statutory rate. On a combined exposure of $5,800,000, even a modest interest rate applied over the duration of litigation could result in a six-figure interest award.

(ii) Attorneys' fees: While Delaware follows the American Rule (each party bears its own fees), exceptions exist for cases involving bad faith or fraud. If a court were to find that Lumos acted in bad faith — either in making the initial representation or in resisting a justified refund — a fee-shifting award is possible. The SAFEs themselves do not contain a fee-shifting provision.

(iii) Consequential damages: These are unlikely in the context of a SAFE that has not converted. The investors have not suffered lost profits or other consequential harm beyond the deployment of capital. However, Vantage Peak could conceivably argue for opportunity cost damages — the return it could have earned by deploying the $3,500,000 elsewhere during the period of the dispute. Such claims are speculative and would face significant proof challenges, but they add to the litigation burden.

The maximum direct exposure is $5,800,000 (the total funded amount) plus interest and fees. Since a successful claim by the investors would ultimately require Lumos to return the funds, a voluntary refund achieves the same economic result without the incremental costs and risks of litigation.

C. Reputational Risk

Reputational risk is, in many respects, a more significant concern than the direct financial exposure. Lumos is a seed-stage company with approximately 4.1 months of post-refund runway. The Company will need to raise additional capital in the near term — potentially within the next three to four months — in order to continue operations and fund the remediation of Prism Core v2.0. Its ability to attract new investors will depend critically on its reputation in the venture ecosystem.

Litigation with Vantage Peak Ventures Fund II — a prominent venture fund with a $185 million fund size and established relationships throughout the technology investment community — would be devastating to Lumos's reputation. The venture capital ecosystem is small and interconnected; news of a fraud dispute with a lead investor would spread rapidly and would deter potential future investors from engaging with the Company. Even the existence of a dispute, if it became public through court filings or industry channels, could impair Lumos's fundraising efforts at a time when the Company can least afford such impairment.

The co-investors, Ridgeline Angel Fund and Canopy Growth Capital, are also active participants in the startup investment community. Their experience with Lumos — positive or negative — will influence the perceptions of other potential investors who may conduct reference checks or otherwise inquire about the Company's track record with its existing investor base. A cooperative and professional resolution of the current situation is far more likely to generate favorable references than a contested dispute.

D. Costs of Defense

The direct costs of defending against fraud and misrepresentation claims would be substantial and would impose a disproportionate burden on a company of Lumos's size and financial position. Litigation in the Delaware Court of Chancery or Superior Court would involve extensive discovery — including document production, depositions of key personnel (CEO Narasimhan, CTO Marsh, board member Watanabe, and potentially members of the development team), expert testimony on product development standards, and potentially review of the Company's internal communications and development records for the entire June–October 2023 period. The costs of discovery alone could easily reach six figures.

Calderwood & Harkness's current engagement for the SAFE financing round has generated fees of $67,340 against a $95,000 fee cap. A litigation matter would fall outside the scope of the current engagement and would involve substantially higher fees. Depending on the complexity and duration of the proceedings, litigation costs could range from $250,000 to $750,000 or more — an amount that Lumos simply cannot afford given its post-refund cash position of approximately $390,000 and monthly burn rate of approximately $95,000.

Beyond legal fees, litigation would consume significant management attention and time. CEO Narasimhan and CTO Marsh would be required to participate in discovery and trial preparation, diverting their attention from the critical tasks of product remediation, customer management, and fundraising. For a fourteen-person company operating on a limited runway, this management distraction would be acutely harmful.

In sum, the costs of defense — in terms of both dollars and management resources — are prohibitive given Lumos's current financial and operational position. The Company cannot afford to litigate, and a strategy premised on defense of the misrepresentation claims is not financially viable.

VII. Treatment of Atlas Fintech Syndicate

Atlas Fintech Syndicate, L.P. signed a non-binding term sheet on October 4, 2023, committing $1,000,000 to the seed financing round. However, the SAFE between Lumos and Atlas Fintech was never executed, and no funds were transferred. The term sheet expressly provides that it is non-binding and does not create any legal obligation on the part of either party to consummate the transaction.

As a result, no contractual obligation exists between Lumos and Atlas Fintech beyond the non-binding term sheet. Atlas Fintech has no claim for return of funds (because no funds were invested), no contractual rights under a SAFE (because no SAFE was executed), and no basis for a misrepresentation claim arising out of the SAFE (because no investment was made in reliance on any representation). Atlas Fintech's withdrawal from the round — whether already communicated or anticipated — requires no refund, no legal action, and no Mutual Termination & Release Agreement.

Lumos may wish, as a matter of good practice and record-keeping, to send a formal written acknowledgment to Atlas Fintech confirming the withdrawal and the termination of the non-binding term sheet. This communication should be professional, brief, and forward-looking, expressing appreciation for Atlas Fintech's interest in the Company and leaving the door open for future engagement. The communication should not reference the product setback, the Vantage Peak dispute, or the circumstances surrounding the termination of the round, as Atlas Fintech is not a party to the dispute and any unnecessary disclosure could create additional risk.

We note that the term sheet with Atlas Fintech was signed on October 4, 2023 — four days before the Peralta validation testing was completed and five days before the report was issued. The timing raises the question of whether Lumos had any obligation to inform Atlas Fintech of the product setback before proceeding to execute the SAFE. Because the SAFE was never executed and no investment was made, this question is moot as a practical matter. However, it is worth noting that if the SAFE had been executed after October 9 (the date of the Peralta report) without disclosure of the validation failure, Lumos's exposure to misrepresentation claims from Atlas Fintech would have been significantly more acute than its exposure to Vantage Peak — because in that scenario, Lumos would have had actual knowledge of the shortfall at the time of the representation. The fact that the Atlas Fintech SAFE was not executed is a fortunate outcome for the Company.

VIII. Treatment of Co-Investor SAFEs (Ridgeline and Canopy Growth)

The Ridgeline Angel Fund, L.P. SAFE ($1,200,000, executed September 22, 2023) and the Canopy Growth Capital LLC SAFE ($1,100,000, executed September 29, 2023) are on identical substantive terms as the Vantage Peak SAFE, including the same $28,000,000 post-money valuation cap, no discount, MFN provision, conversion triggers, and governing law. The same legal analysis regarding termination provisions, refund obligations, and misrepresentation exposure that applies to the Vantage Peak SAFE applies wi

PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT WORK PRODUCT
MEMORANDUM
To: Patricia Dunmore, Partner, Calderwood & Harkness LLP
From: Omar Siddiqui, Associate, Calderwood & Harkness LLP
Date: October 16, 2023
Re: Lumos Analytics Inc. — Strategic Analysis of SAFE Termination Provisions, Refund Obligations, and Misrepresentation Exposure Following Vantage Peak Withdrawal Request
Matter No.: 1008-00003
Reviewed by: Patricia Dunmore
Right-click to update Table of Contents
I. Executive Summary
This memorandum analyzes the legal position and available strategic options for our client, Lumos Analytics Inc. ("Lumos" or the "Company"), following the October 15, 2023 request by Vantage Peak Ventures Fund II, L.P. ("Vantage Peak") for the return of its $3,500,000 investment under a Simple Agreement for Future Equity ("SAFE"), citing alleged material misrepresentation regarding the readiness of the Company's Prism Core v2.0 machine-learning compliance scoring module. This memorandum addresses the enforceability of the SAFE termination provisions, Lumos's refund obligations (both contractual and equitable), the Company's exposure to fraud and misrepresentation claims under Delaware law, and the recommended negotiation strategy for resolving this matter expeditiously and with minimal long-term damage to the Company.
The factual predicate for this crisis is as follows. On October 8, 2023, Peralta IP Consulting LLC ("Peralta"), a third-party validation consultant engaged by Lumos, completed functionality and accuracy validation testing of the Prism Core v2.0 machine-learning module. Peralta issued its report on October 9, 2023, revealing that the module achieved only 61% accuracy against a target benchmark of 92% — a shortfall of more than thirty percentage points that renders the product materially unfit for commercial deployment in its current state. On October 10, 2023, Lumos's Chief Technology Officer, Elliot Marsh, disclosed the validation failure to the Company's board of directors. The board convened a meeting on October 12, 2023, at which it determined that the failure constitutes a material product setback and debated the Company's disclosure obligations to its investors. On October 13, 2023, CEO Priya Narasimhan disclosed the setback to Vantage Peak's deal lead, Samantha Reyes. Two days later, on October 15, 2023, Vantage Peak communicated its request for the full return of its $3,500,000 SAFE investment, alleging that Lumos had made material misrepresentations regarding the readiness of Prism Core v2.0 in its August 2023 investor pitch materials.
It is anticipated that Lumos's co-investors in this financing round — Ridgeline Angel Fund, L.P. ("Ridgeline"), which funded $1,200,000 under a SAFE executed September 22, 2023, and Canopy Growth Capital LLC ("Canopy Growth"), which funded $1,100,000 under a SAFE executed September 29, 2023 — will follow Vantage Peak's lead and submit withdrawal requests in the near term. Additionally, Atlas Fintech Syndicate, L.P. ("Atlas Fintech"), which signed a term sheet on October 4, 2023 committing $1,000,000 but never executed a SAFE or transferred funds, is expected to withdraw from the round entirely. The total funded amount at risk is $5,800,000, representing the aggregate of all three executed and funded SAFEs ($3,500,000 + $1,200,000 + $1,100,000).
Based on the analysis that follows, our recommendation is that Lumos negotiate mutual termination of all three funded SAFEs with full refund of the aggregate $5,800,000 in purchase amounts, structured through Mutual Termination & Release Agreements that include broad mutual releases, covenants not to sue, no admission of liability by either party, mutual non-disparagement provisions, and robust confidentiality obligations. While Lumos has colorable defenses to both fraud and negligent misrepresentation claims — most notably the absence of scienter and the forward-looking nature of the "beta-ready by Q4 2023" representation — the risk/reward calculus decisively favors resolution. The litigation risk is meaningful, the reputational damage of a public dispute with a prominent venture fund would be severe, the funds have not been materially deployed and remain available for return, and the incremental costs of defense (legal fees, discovery burdens, management distraction) would be disproportionate to any conceivable benefit of resistance. Full refund, properly documented, is the cleanest path to preserving Lumos's viability and reputation for future fundraising efforts.
II. Factual Background
A. The SAFE Financing Round
Lumos Analytics Inc. is a Delaware C-corporation (EIN: 87-3491026; Delaware Secretary of State File No. 7394821), headquartered at 340 Folsom Street, Suite 1100, San Francisco, CA 94105. The Company is a seed-stage SaaS/fintech analytics company operating in the financial regulatory compliance and predictive risk scoring space. Lumos was incorporated in Delaware in 2021 and has maintained its principal place of business in San Francisco since inception.
In the summer of 2023, Lumos initiated a seed financing round with a total target of $6,800,000 in Post-Money SAFEs. The SAFEs were based on the Calderon Partners LLC ("YC") standard Post-Money SAFE form, with certain modifications negotiated with the lead investor's counsel. The terms of the round included a post-money valuation cap of $28,000,000 and no discount rate. The round was authorized by the Lumos board of directors via a written consent dated August 30, 2023, signed by all three directors: Priya Narasimhan (CEO and director), Elliot Marsh (CTO and director), and Kenji Watanabe (independent director and observer designee of Ridgeline Angel Fund from the pre-seed round).
The lead investor in the round was Vantage Peak Ventures Fund II, L.P., a Delaware limited partnership. Vantage Peak's general partner is Vantage Peak Capital Management LLC, whose managing partners are Catherine Aldridge and Raymond Petrov. The deal was sourced and led on the Vantage Peak side by Samantha Reyes, a principal at the firm. Vantage Peak committed $3,500,000 to the round. The SAFE between Lumos and Vantage Peak was executed on September 12, 2023, and funds in the amount of $3,500,000 were wired to Lumos's operating account at Silicon Valley Commerce Bank ("SVCB") (Account No. 8801-4427-3390) on the same date. In connection with the SAFE, Lumos and Vantage Peak executed a Pro Rata Rights Side Letter, also dated September 12, 2023, granting Vantage Peak certain participation rights in future equity financings.
Three co-investors participated in or committed to the round, with the following details:
•  Ridgeline Angel Fund, L.P.: Ridgeline executed a SAFE for $1,200,000 on September 22, 2023. Funds were wired to the Lumos SVCB operating account on the same date. Ridgeline is also an existing pre-seed SAFE holder, having invested $500,000 under a SAFE with an $8,000,000 post-money valuation cap in August 2022. Ridgeline's pre-seed SAFE remains outstanding and is addressed separately in Section IX of this memorandum.
•  Canopy Growth Capital LLC: Canopy Growth executed a SAFE for $1,100,000 on September 29, 2023. Funds were wired to the Lumos SVCB operating account on the same date.
•  Atlas Fintech Syndicate, L.P.: Atlas Fintech committed $1,000,000 to the round and signed a non-binding term sheet on October 4, 2023. However, the SAFE was never executed, and no funds were transferred. Atlas Fintech's situation is addressed separately in Section VII.
All three executed SAFEs (Vantage Peak, Ridgeline, and Canopy Growth) were on identical substantive terms: a post-money valuation cap of $28,000,000, no discount, a most-favored-nation ("MFN") provision, and three conversion triggers — (i) an Equity Financing of at least $1,000,000 in aggregate new issuance, (ii) a Liquidity Event (defined to include a change of control, direct listing, or initial public offering), and (iii) a Dissolution Event. All three SAFEs are governed by Delaware law.
The total amount funded during the round was $5,800,000 ($3,500,000 from Vantage Peak + $1,200,000 from Ridgeline + $1,100,000 from Canopy Growth). The round remained open with respect to Atlas Fintech's $1,000,000 commitment, which would have brought the total to $6,800,000 against the round target.
B. The Product Setback — Prism Core v2.0
Lumos's core product, Lumos Prism, is an AI-driven financial analytics platform that provides real-time regulatory compliance dashboards and predictive risk scoring to mid-market financial institutions. The platform integrates with clients' existing data infrastructure to deliver automated compliance monitoring, anomaly detection, and risk assessment capabilities. As of July 2023, the platform generated monthly recurring revenue ("MRR") of approximately $38,000, derived from a growing but still modest customer base.
Prism Core v2.0 is the designation for the next-generation machine-learning compliance scoring module that Lumos has been developing as the centerpiece of its product roadmap. Prism Core v2.0 was intended to represent a significant advancement over the Company's existing compliance scoring capabilities by incorporating proprietary machine-learning algorithms designed to deliver substantially higher predictive accuracy and broader regulatory coverage. The technology underlying Prism Core v2.0 is the subject of U.S. Provisional Patent Application No. 63/987,214, filed on June 15, 2023, which covers the Prism Core predictive risk algorithm.
In the investor pitch materials circulated by Lumos to prospective investors in August 2023 — including the pitch deck, financial projections, and product roadmap summary — the Company represented Prism Core v2.0 as "beta-ready by Q4 2023." This representation was a central element of the investment thesis presented to Vantage Peak and the other round participants, as the commercial launch of Prism Core v2.0 was positioned as the primary near-term value creation event that would support the Company's $28,000,000 post-money valuation cap.
In order to validate the functionality and accuracy of the Prism Core v2.0 module, Lumos engaged Peralta IP Consulting LLC, a technology consulting firm led by Dr. Amir Farouk, to conduct independent third-party validation testing. Peralta completed its testing on October 8, 2023 and issued its final report on October 9, 2023. The report's findings were materially adverse: Prism Core v2.0 achieved only 61% accuracy against the 92% benchmark target that Lumos had established as the minimum threshold for commercial viability. This thirty-one-percentage-point shortfall represents a fundamental deficiency in the module's predictive capabilities and, in the assessment of CTO Elliot Marsh, would require an estimated four to six months of additional development work to remediate.
CTO Marsh disclosed the validation failure to the Lumos board of directors on October 10, 2023. The board convened a meeting on October 12, 2023, at which it formally determined that the Peralta validation failure constitutes a material product setback. The board also debated the Company's disclosure obligations under the information rights provisions negotiated into the SAFEs, as well as any general duties to update investors regarding material changes in circumstances. Following the board meeting and after consultation with this firm, CEO Priya Narasimhan notified Vantage Peak's deal lead, Samantha Reyes, of the product setback on October 13, 2023.
C. Vantage Peak's Response
On October 15, 2023 — two days after CEO Narasimhan's disclosure — Vantage Peak communicated its request for the return of the full $3,500,000 SAFE purchase amount. The request was made verbally by Samantha Reyes to Priya Narasimhan and was characterized as based on alleged material misrepresentation regarding product readiness. Vantage Peak has retained Whitfield Harte & Associates LLP as outside counsel in this matter. Whitfield Harte is a Palo Alto-based firm with offices at 3000 El Camino Real, Suite 500, Palo Alto, CA 94306. The lead partner on the matter is Jonathan Whitfield; the associate is Megan Trost. Whitfield Harte previously served as investor's counsel during the SAFE negotiation and provided the September 8, 2023 markup of the SAFE form, as well as subsequent revisions through September 11, 2023.
We anticipate receipt of a formal demand letter from Whitfield Harte imminently. As of the date of this memorandum (October 16, 2023), no formal written demand has been received, but based on the tone of the October 15 communication and the engagement of litigation-capable counsel, we expect a letter setting forth Vantage Peak's legal theories and demand within the next two to five business days. (Note: the formal demand letter was received on October 18, 2023, and will be addressed in a supplemental memorandum.)
D. Lumos's Financial Position
A clear understanding of Lumos's financial position is critical to evaluating the strategic options and the Company's capacity to fund either a refund or a litigation defense. As of the relevant dates, Lumos's financial position is as follows:
•  Monthly recurring revenue: Approximately $38,000 as of July 2023.
•  Monthly burn rate: Approximately $95,000, inclusive of payroll (14 full-time employees), office lease, cloud infrastructure costs, and general and administrative expenses.
•  Pre-round cash position: Approximately $420,000 in the SVCB operating account prior to the receipt of round proceeds.
•  Revolving credit line: $200,000 revolving line of credit at SVCB, with $0 drawn as of August 2023. The credit line remains available as of the date of this memorandum.
•  Total funds received during the round: $5,800,000 (as detailed above).
•  Current estimated cash position: Approximately $6,190,000, reflecting the pre-round cash position plus the $5,800,000 in round proceeds, less approximately $30,000 in net operating expenses and legal fees during the round period (September–October 2023), offset by revenue received during the same period.
•  Post-full-refund cash position: If Lumos were required to return the full $5,800,000 in funded SAFE proceeds, the Company would be left with approximately $390,000 in operating cash.
•  Post-refund runway: At the current monthly burn rate of approximately $95,000, a cash position of $390,000 would provide the Company with approximately 4.1 months of operating runway before exhausting available funds. This figure does not account for the undrawn $200,000 revolving credit line, which, if fully drawn, would extend the runway to approximately 6.2 months.
•  Headcount: 14 full-time employees as of August 2023. Payroll is the largest component of the monthly burn rate.
The critical takeaway from this financial analysis is that Lumos has not materially deployed the SAFE proceeds. The $5,800,000 in round funds remains substantially intact in the SVCB operating account and is available for return. This fact significantly simplifies the mechanics of a full refund and eliminates any argument that the Company lacks the capacity to make investors whole.
III. Analysis of SAFE Termination Provisions
A. Structure of the Post-Money SAFE
The SAFE instruments executed with Vantage Peak, Ridgeline, and Canopy Growth are based on the YC standard Post-Money SAFE form, with certain modifications negotiated during the September 2023 documentation process. As a threshold matter, it is important to understand the structural characteristics of the SAFE instrument that are relevant to the termination analysis.
A SAFE is not a debt instrument. It does not bear interest, does not have a maturity date, and does not impose any repayment obligation on the issuer. It is also not an equity security at the time of issuance — the SAFE holder does not receive shares of the company's stock and does not have voting rights, dividend rights, or other equity holder rights upon execution. Rather, a SAFE is a contractual right to future equity: the investor pays a purchase amount in exchange for the company's commitment to issue equity to the investor upon the occurrence of specified conversion events. The SAFE is, in essence, a contingent obligation that remains outstanding until triggered by a qualifying event.
The conversion triggers under the Lumos SAFEs are consistent with the standard YC form and include three events:
(1) Equity Financing: A bona fide transaction in which the Company issues and sells preferred stock in a new round of equity financing with aggregate new proceeds to the Company of at least $1,000,000.
(2) Liquidity Event: A change of control of the Company, a direct listing of the Company's securities on a public exchange, or an initial public offering.
(3) Dissolution Event: A voluntary termination of operations, a general assignment for the benefit of creditors, or any other liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary.
In the event of a Dissolution Event, the SAFE provides for the return of the purchase amount to SAFE holders (or a lesser pro rata amount from available assets) in priority to holders of common stock but junior to creditors. In all other respects, the SAFE does not contemplate or provide for a return of the purchase amount to the investor.
Critically, the standard YC SAFE form does not include any express termination-for-convenience provision. There is no mechanism by which either party may unilaterally terminate the instrument and trigger a return of funds outside of a Dissolution Event.
B. Absence of Contractual Termination Right
Having reviewed the executed SAFE agreements in full, including the modifications negotiated by Whitfield Harte during the September 2023 documentation process, we confirm that none of the three executed SAFEs contains a unilateral investor termination or withdrawal provision. There is no "put" right, no "material adverse change" or "MAC" clause, and no other provision that would permit an investor to demand the return of its purchase amount based on adverse developments in the Company's business, product development, financial condition, or prospects.
This is consistent with the fundamental design of the SAFE instrument. The YC SAFE was intentionally structured to be irrevocable once executed and funded: the investor's capital is committed to the company, and the investor's return is entirely contingent on the occurrence of a conversion event. The investor bears the risk that no conversion event may ever occur and that the investment may be lost entirely — a feature that distinguishes the SAFE from a loan or other repayable instrument.
Accordingly, Vantage Peak does not have a contractual right under the terms of the SAFE to compel the return of its $3,500,000 purchase amount. The same analysis applies with equal force to the Ridgeline SAFE ($1,200,000) and the Canopy Growth SAFE ($1,100,000). The investors' only contractual path to recovery of their purchase amounts would be through a Dissolution Event (in which case the amounts would be returned only from available assets and subject to prior creditor claims) or through a negotiated mutual termination.
We note that Whitfield Harte, as experienced venture counsel, is undoubtedly aware of this structural reality. Vantage Peak's demand is therefore best understood not as an assertion of a contractual right but rather as a demand premised on extra-contractual legal theories (primarily fraud and misrepresentation) coupled with a practical expectation that Lumos will agree to a negotiated resolution to avoid the costs and risks of contested proceedings.
C. Mutual Termination as the Operative Path
While no party has a unilateral right to terminate the SAFEs, both parties retain the ability to agree to terminate the instruments by mutual written consent. Mutual termination is the operative legal mechanism through which a refund can be effectuated in an orderly and documented manner.
A mutual termination would require the negotiation and execution of a definitive agreement addressing several key matters:
(i) The refund amount and payment timing;
(ii) Broad mutual releases of all claims arising out of or related to the SAFE, the financing round, and the circumstances giving rise to the termination;
(iii) Continuing confidentiality obligations of both parties with respect to non-public information exchanged during the investment process and the terms of the termination itself;
(iv) Treatment of any proprietary information, intellectual property, or trade secrets shared with the investor during the due diligence process;
(v) Termination of any ancillary agreements (such as the Pro Rata Rights Side Letter with Vantage Peak);
(vi) Representations regarding the absence of liens, encumbrances, or third-party claims on the SAFE or the refund proceeds; and
(vii) Appropriate no-admission-of-liability language and mutual non-disparagement covenants.
We recommend structuring these agreements as "Mutual Termination & Release Agreements," with separate agreements for each of the three funded investors. The use of separate agreements allows for customization where necessary — most importantly, the Ridgeline agreement must include a carve-out preserving Ridgeline's pre-seed SAFE, as discussed further in Section VIII below.
D. Impact of Dissolution Event Provisions
As noted above, in the event of a Dissolution Event, the SAFE provides for return of the purchase amount (or a lesser pro rata amount from available assets) to SAFE holders in priority to common stockholders but junior to creditors. While a Dissolution Event is not currently applicable, this provision is relevant to the broader strategic analysis for two reasons.
First, the limited runway available to Lumos post-refund (approximately 4.1 months at current burn rates) raises the realistic possibility that the Company could face a Dissolution Event in the first half of 2024 if it is unable to secure alternative financing. If that were to occur while the SAFEs remain outstanding (i.e., if Lumos refuses to refund and the SAFEs are not terminated), the investors would be entitled to return of their purchase amounts from available assets under the Dissolution Event provisions — but only to the extent funds are available at that point, which could be substantially less than the full purchase amounts given ongoing cash consumption. This dynamic actually strengthens the case for a prompt full refund while the funds are still available, rather than risking a scenario in which the Company's assets are depleted and investors recover only a fraction of their investment.
Second, the Dissolution Event provision underscores the SAFE's structural bias toward investor recovery in downside scenarios. Vantage Peak and the co-investors are acutely aware that their best path to full recovery is a negotiated refund while the Company remains solvent and the funds are intact.
IV. Contractual and Equitable Refund Obligations
A. Contractual Basis for Refund
As established in Section III above, no express refund obligation exists under the terms of the executed SAFEs outside of a Dissolution Event. The SAFEs do not contain any provision entitling an investor to demand return of the purchase amount based on product setbacks, failure to meet development milestones, material adverse changes in the Company's business, or any other adverse event short of dissolution. The instruments are, by their terms, irrevocable commitments of capital in exchange for contingent equity rights.
Vantage Peak's refund request is therefore not grounded in any contractual right under the SAFE itself. Rather, it is premised on an extra-contractual theory: that the SAFE was procured through material misrepresentation regarding the readiness of Prism Core v2.0, and that this misrepresentation vitiates Vantage Peak's consent to the instrument, rendering it voidable at the investor's election. This theory sounds in tort and equity rather than in contract, and the appropriate remedy — if the theory were sustained — would be equitable rescission, not contractual damages.
B. Equitable Rescission
Under Delaware law, a contract procured by fraud or material misrepresentation may be rescinded at the election of the injured party. Rescission is an equitable remedy that returns the parties to the status quo ante — that is, the position they occupied before the transaction. In the context of a SAFE, rescission would require Lumos to return the $3,500,000 purchase amount to Vantage Peak, and Vantage Peak would surrender its SAFE and all rights thereunder.
The elements for equitable rescission based on misrepresentation under Delaware law are as follows:
(1) A false representation of a material fact;
(2) Knowledge of the falsity of the representation or reckless disregard for its truth or falsity (in the case of fraud), or lack of reasonable grounds for believing the representation to be true (in the case of negligent misrepresentation);
(3) An intent to induce the other party to act in reliance upon the representation;
(4) Justifiable reliance by the other party upon the representation; and
(5) Resulting damage or prejudice to the other party.
If a court were to find these elements satisfied and order rescission, Lumos would be required to return the full purchase amount, and could additionally be liable for prejudgment interest, reasonable attorneys' fees in appropriate circumstances, and costs. The potential for these incremental liabilities is a further consideration weighing in favor of a voluntary resolution.
Equitable rescission is a particularly attractive remedy for Vantage Peak in this context because the SAFE has not yet converted to equity. There are no realized gains or losses, no dividends, and no other equity-related benefits that would complicate the unwinding of the transaction. The remedy of rescission here is, as a practical matter, simply a return of cash — making it straightforward to implement and easy for a court to order.
C. Restitution and Unjust Enrichment
As an alternative or supplementary equitable theory, Vantage Peak could seek restitution of the $3,500,000 under principles of unjust enrichment. Under this theory, if the SAFE were deemed void ab initio (i.e., void from its inception due to a fundamental defect in formation, such as fraud), Lumos's retention of the purchase amount would constitute unjust enrichment because there would be no valid contractual basis for the Company's receipt and retention of the funds.
Lumos's principal defense to an unjust enrichment claim would be that the SAFE is a valid and enforceable contract, and that funds received pursuant to a valid contractual obligation cannot give rise to an unjust enrichment claim. This defense is generally sound under Delaware law, which recognizes that unjust enrichment claims are precluded where a valid contract governs the subject matter of the dispute. However, this defense is circular in the present context: if the SAFE is voidable due to fraud, the contractual defense to unjust enrichment falls away.
As a practical matter, the unjust enrichment theory adds little to Vantage Peak's position beyond what is already available through rescission, but it provides an alternative legal basis and could be pled in the alternative if litigation were to ensue.
D. Practical Considerations
Several practical considerations bear on the refund analysis and support the recommendation of full refund:
Availability of funds. As noted in Section II.D, the $5,800,000 in aggregate SAFE proceeds has not been materially deployed. The funds remain substantially intact in the Lumos SVCB operating account and are readily available for return. This eliminates any argument that Lumos lacks the financial capacity to make investors whole and removes a potential source of dispute regarding the mechanics of refund.
Partial refund or negotiated haircut. It is theoretically possible that Lumos could attempt to negotiate a partial refund — retaining a portion of the funds to cover administrative costs, legal fees, or other expenses incurred in connection with the round. However, this approach is strongly inadvisable for several reasons. First, the amounts at issue (likely in the range of $50,000–$100,000 in incremental costs) are trivial relative to the $5,800,000 total, and insisting on a haircut would signal bad faith and likely escalate the dispute. Second, any deduction from the refund amount would need to be justified and documented, creating additional points of contention. Third, Vantage Peak's counsel at Whitfield Harte would almost certainly reject a partial refund and treat it as an occasion to escalate to formal litigation. The marginal benefit of retaining a small portion of the funds is far outweighed by the risk of escalation.
Reputational preservation. A full and prompt refund, accompanied by appropriate documentation and mutual releases, sends a signal to the market that Lumos is acting with integrity and professionalism in the face of a product setback. This is the single most important consideration for a seed-stage company that will need to return to the capital markets in the near term.
Based on the foregoing, we recommend that Lumos agree to a full refund of the $5,800,000 in aggregate SAFE purchase amounts as the centerpiece of the resolution strategy.
V. Fraud and Misrepresentation Exposure Under Delaware Law
A. The Alleged Misrepresentation
The core factual predicate for Vantage Peak's misrepresentation claim is the representation made in Lumos's August 2023 investor pitch materials that Prism Core v2.0 would be "beta-ready by Q4 2023." This representation appeared in the product roadmap section of the pitch deck that was circulated to Vantage Peak and other prospective investors during the fundraising process, and it was reiterated verbally by CEO Narasimhan and CTO Marsh during investor meetings in August and early September 2023.
At the time this representation was made (August 2023), third-party validation testing by Peralta IP Consulting had not yet been conducted. Peralta was engaged to validate the functionality and accuracy of the module, and its testing was not completed until October 8, 2023 — nearly two months after the pitch materials were circulated and approximately one month after Vantage Peak executed its SAFE on September 12, 2023.
When the Peralta report was issued on October 9, 2023, it revealed a fundamental shortfall: the Prism Core v2.0 module achieved only 61% accuracy against the 92% benchmark target that Lumos had established as the minimum threshold for commercial viability and beta deployment. CTO Marsh's assessment is that four to six months of additional development will be required to remediate the accuracy deficiency, meaning that a realistic beta-readiness date is now Q2 2024 at the earliest — a delay of at least one full quarter beyond the timeline represented to investors, and potentially two.
Vantage Peak's position, as communicated verbally by Samantha Reyes on October 15, 2023, is that the "beta-ready by Q4 2023" representation was materially false or misleading when made, and that the Company either knew or should have known that the product was not on track to meet this timeline. Vantage Peak asserts that it relied on this representation in deciding to invest $3,500,000 and would not have invested — or would have invested on materially different terms — had it known the true state of the product's development.
The key legal question is whether the "beta-ready by Q4 2023" statement constitutes a statement of present fact susceptible to a misrepresentation claim, or whether it is properly characterized as a forward-looking projection or expression of management's expectations — a category of statement that is generally more difficult to challenge as fraudulent or misleading. A secondary but important question is whether Lumos had a reasonable basis for the statement at the time it was made.
B. Common-Law Fraud (Delaware)
Under Delaware law, the elements of a common-law fraud claim are well established:
(1) A false representation of a material fact;
(2) Made with knowledge of its falsity or with reckless indifference to whether it is true or false (scienter);
(3) With the intent to induce the other party to act or refrain from acting;
(4) Reasonable reliance by the other party upon the representation; and
(5) Resulting damage.
We analyze each element below as applied to the facts at hand.
Falsity. The representation at issue — "beta-ready by Q4 2023" — is fundamentally a statement about the anticipated future state of a product under development. It is framed in forward-looking terms and relates to a timeline that had not yet arrived at the time the representation was made. Under Delaware law, statements regarding future events, predictions, and expectations are generally not actionable as fraud unless they are accompanied by a misrepresentation of present fact — for example, a false statement about the current state of development, the current results of testing, or the current probability of meeting a timeline. Lumos's strongest defense on this element is that the "beta-ready by Q4 2023" statement was a good-faith projection of the development timeline based on the information available to the CTO at the time, not a guarantee of a future outcome.
However, this defense is not airtight. If Vantage Peak can demonstrate that Lumos had internal data, testing results, or other information at the time of the August 2023 pitch that suggested the module was not on track to achieve the 92% accuracy benchmark by Q4 2023, the forward-looking characterization could be undermined. A statement of expectation is actionable if the speaker does not actually hold the stated expectation or has no reasonable basis for it. We have not yet had the opportunity to conduct a thorough review of the Company's internal development records, emails, and Brightmoor Data Systems for the June–August 2023 period, and we flag this as a critical area for factual investigation. If internal communications reveal that CTO Marsh or other members of the development team harbored doubts about the Q4 timeline prior to the pitch, Vantage Peak's case would be materially strengthened.
Materiality. Product readiness is unambiguously material to an investor's decision to invest in a seed-stage SaaS company whose principal value proposition is its technology platform. Lumos Prism is the Company's core product, and Prism Core v2.0 is the next-generation module that was positioned in the pitch as the primary near-term value driver. The Company's MRR of approximately $38,000 per month is insufficient to support its operations independently, making the successful commercialization of Prism Core v2.0 essential to the Company's growth trajectory and, ultimately, to the creation of investor value. The 61% vs. 92% accuracy gap is not a minor deviation from plan; it represents a fundamental deficiency that renders the module unfit for commercial deployment and requires months of additional development. Vantage Peak will have no difficulty establishing materiality.
Scienter. This is the most significant obstacle to Vantage Peak's fraud claim and the element on which Lumos's defense is strongest. Scienter requires proof that the defendant made the representation with knowledge of its falsity or with reckless disregard for whether it was true or false. At the time the pitch materials were circulated (August 2023) and the SAFE was executed (September 12, 2023), the Peralta third-party validation had not yet been conducted, and the validation failure was not discovered until October 8–9, 2023. CTO Marsh did not disclose the failure to the board until October 10, 2023, and there is no evidence presently known to us that any member of Lumos's management team was aware that the module would fail the accuracy benchmark at the time the "beta-ready by Q4 2023" representation was made.
That said, the scienter analysis is not entirely free from risk. Vantage Peak's counsel at Whitfield Harte may pursue several lines of argument:
(a) Internal testing conducted prior to the Peralta engagement may have revealed accuracy or performance concerns that were known to the development team but not disclosed to investors. If pre-Peralta testing data exists showing accuracy rates materially below the 92% target, this could establish that Lumos's management knew or should have known that the module was not on track for Q4 beta-readiness.
(b) CTO Marsh's four-to-six-month remediation estimate, rendered almost immediately after the Peralta report, may suggest that the nature of the deficiencies was already understood or foreseeable by the technical team, even if the precise accuracy figure was not known.
(c) The engagement of Peralta itself may be characterized as an acknowledgment by Lumos that the module's readiness was uncertain — if the Company had confidence in the product's accuracy, why was third-party validation deemed necessary before (rather than after) the stated beta launch?
While these arguments do not establish scienter on the current factual record, they create risks in discovery. A fraud claim would entitle Vantage Peak to broad discovery of Lumos's internal communications, development records, testing data, and project management files for the relevant period. If such discovery were to reveal unfavorable documents — even if not conclusive on scienter — the litigation dynamics would shift significantly in Vantage Peak's favor.
Reliance and Damages. Vantage Peak will argue that it relied on the "beta-ready by Q4 2023" representation in making its investment decision and that it suffered damage by deploying $3,500,000 in capital into a company with a materially different product trajectory than the one represented. Given that the product roadmap was a central feature of the pitch and the Q4 beta timeline was directly linked to the Company's growth projections and valuation, reliance is likely to be established. Damages in a rescission action are straightforward: the return of the $3,500,000 purchase amount.
Overall Assessment of Fraud Claim. Vantage Peak's common-law fraud claim faces significant hurdles on the scienter element based on the facts currently known to us. The forward-looking nature of the representation, the absence of knowledge of the validation failure at the time the SAFE was executed, and the inherent uncertainty of startup product development timelines all support Lumos's defense. However, the factual record is incomplete — particularly with respect to internal development data and communications — and discovery poses meaningful risks. We assess the probability of Vantage Peak prevailing on a fraud claim at approximately 25–35%, with the range depending heavily on what internal documents would reveal.
C. Negligent Misrepresentation
Negligent misrepresentation presents a more significant risk than common-law fraud because it requires a lower culpability threshold. The elements under Delaware law are:
(1) A misrepresentation of a material fact;
(2) Made without reasonable grounds for believing the statement to be true;
(3) With the intent to induce the other party to act in reliance upon the representation;
(4) Justifiable reliance by the other party; and
(5) Resulting damage.
The critical distinction from fraud is that negligent misrepresentation does not require proof of intentional deceit or reckless disregard for truth (scienter). Instead, it requires only that the defendant lacked reasonable grounds for believing the statement to be true — in other words, that the defendant was negligent in making the representation. This is a materially lower bar.
Applied to the present facts, the question becomes: did Lumos have a reasonable basis for representing Prism Core v2.0 as "beta-ready by Q4 2023" when the module had not yet undergone third-party validation and, as it turned out, was achieving only 61% accuracy against a 92% target? The thirty-one-percentage-point accuracy shortfall is not a marginal miss; it is a fundamental deficiency that suggests either (a) the module was at a much earlier stage of development than represented, or (b) the Company's internal assessment of the module's readiness was conducted without adequate rigor.
Vantage Peak will argue that a company representing a product as "beta-ready by Q4 2023" to prospective investors has an obligation to ensure that this representation is supported by credible internal data, and that circulating such a representation without first completing (or at least substantially completing) validation testing reflects a lack of reasonable care. The magnitude of the accuracy shortfall — 61% vs. 92% — may suggest that reasonable internal testing would have identified the risk of failure well before the pitch materials were circulated.
Lumos's defense to the negligent misrepresentation theory is that the "beta-ready by Q4 2023" representation reflected CTO Marsh's good-faith assessment of the development timeline based on internal progress metrics available at the time; that the validation failure was an unexpected and unforeseeable outcome that resulted from the complexity of the machine-learning algorithms rather than any deficiency in the development process; and that startup product development timelines are inherently uncertain, a reality that sophisticated venture investors such as Vantage Peak understand and accept. Lumos may further argue that the pitch deck's use of "beta-ready" language (as opposed to "commercially launched" or "fully validated") itself communicates that the product was not yet in final form and that further testing and iteration were anticipated.
These defenses have some merit, but they are weaker than Lumos's defenses to the fraud claim. The core problem is the magnitude of the shortfall. If the module had achieved 87% accuracy against a 92% target, the argument that the miss was unforeseeable and within the expected range of uncertainty would be far stronger. A 61% result suggests a more fundamental problem that may have been identifiable through internal testing. Moreover, the fact that Lumos chose to engage a third-party validator (Peralta) before the beta launch can be read as an implicit acknowledgment that the module's readiness was uncertain — which in turn undermines the argument that the "beta-ready by Q4 2023" representation was made on reasonable grounds.
Risk Assessment. We assess the probability of Vantage Peak prevailing on a negligent misrepresentation claim at approximately 40–55%. This represents a moderate-to-significant litigation risk, particularly because the claim is less dependent on discovering evidence of intentional misconduct and more focused on the reasonableness of the representation given the circumstances. The magnitude of the accuracy shortfall is a powerful fact that any factfinder would weigh heavily.
D. SAFE Contractual Defenses
Notwithstanding the analysis above, Lumos has several contractual defenses that may limit its exposure to misrepresentation claims:
Integration clause. The executed SAFEs contain an integration clause providing that the SAFE constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements, understandings, and representations, whether written or oral. Lumos could argue that any pre-contractual representations made in the pitch materials — including the "beta-ready by Q4 2023" statement — were superseded and extinguished by the executed SAFE, which does not contain any representation regarding product readiness, development timelines, or accuracy benchmarks.
This argument has some force, particularly with respect to negligent misrepresentation claims. Delaware courts have generally recognized that sophisticated parties who negotiate and execute integrated agreements may not later rely on pre-contractual representations that are not incorporated into the final agreement. However, this defense is subject to a critical limitation: Delaware courts have consistently held that integration clauses do not bar fraud claims based on extra-contractual representations, under the longstanding principle that a party cannot contractually insulate itself from its own fraud. See, e.g., RAA Mgmt., LLC v. Savage Sports Holdings, Inc., 45 A.3d 107 (Del. 2012); Abry Partners V, L.P. v. F & W Acquisition LLC, 891 A.2d 1032, 1058 (Del. Ch. 2006). This principle may extend to negligent misrepresentation in certain circumstances, though the case law is less developed on this point.
Absence of representations and warranties. The standard YC Post-Money SAFE does not include investor-protective representations and warranties from the issuer. Unlike a typical Series Seed or Series A stock purchase agreement — which typically contains detailed representations regarding the company's intellectual property, products, material contracts, compliance, litigation, and financial condition — the SAFE is a deliberately streamlined instrument that does not include these protections. The absence of a specific product-readiness warranty in the SAFE strengthens Lumos's argument that Vantage Peak did not bargain for, and was not entitled to rely upon, specific assurances regarding the state of Prism Core v2.0 development.
Limitations of liability and disclaimers. The standard YC SAFE form does not typically include limitation-of-liability or disclaimer provisions. We have reviewed the September 8 Whitfield Harte markup and the subsequent September 11 revised draft for any negotiated additions in this area. The modifications to the standard form were relatively limited and focused primarily on information rights, MFN mechanics, and minor definitional clarifications. No limitation-of-liability or disclaimer provisions were added. This means there is no contractual cap on damages or explicit disclaimer of extra-contractual representations that Lumos could invoke.
Overall assessment of contractual defenses. The integration clause and the absence of representations and warranties provide a useful defensive framework, particularly against negligent misrepresentation claims. However, these defenses are unlikely to bar a fraud claim entirely if Vantage Peak can establish the requisite elements, and they add complexity and cost to any litigation without guaranteeing a favorable outcome. The contractual defenses are best understood as tools for settlement leverage rather than as dispositive shields.
E. Duty to Update / Continuing Disclosure
A distinct but related area of exposure concerns Lumos's duty to update investors once the Prism Core v2.0 validation failure became known. Even if the initial "beta-ready by Q4 2023" representation was made in good faith and on reasonable grounds at the time (August 2023), Lumos may have had a duty to promptly correct or update that representation once the Peralta report revealed it to be inaccurate.
The SAFEs include information rights provisions that were negotiated during the documentation process with Whitfield Harte. The scope of these provisions — including any affirmative reporting obligations, notice requirements for material events, and timelines for communication — should be reviewed carefully against the actual course of events. We note that the September 8 Whitfield Harte markup and the September 11 revised draft introduced certain enhanced information rights provisions; the precise terms and their applicability to the present circumstances require close analysis and are addressed in greater detail in the separate Calderwood & Harkness memorandum on internal disclosure obligations dated October 12, 2023.
As a general matter under Delaware law, an issuer that learns of a material change in circumstances that renders prior representations misleading may have a duty to correct or update those representations, particularly where the prior representations were made in connection with a securities transaction and the transaction — or a related ongoing course of dealing — continues. Here, the SAFE financing round was still open at the time the Peralta report was issued: Atlas Fintech's $1,000,000 SAFE had not yet been executed, and the round had not formally closed. The fact that the transaction was ongoing may heighten Lumos's duty to disclose material developments to existing and prospective investors.
The timeline of Lumos's disclosure is as follows:
•  October 8, 2023: Peralta completes validation testing.
•  October 9, 2023: Peralta issues its report showing 61% accuracy.
•  October 10, 2023: CTO Marsh discloses the failure to the board.
•  October 12, 2023: Board meets, determines the failure is a material setback, and debates disclosure obligations.
•  October 13, 2023: CEO Narasimhan discloses the setback to Vantage Peak's Samantha Reyes.
Lumos disclosed the product setback to Vantage Peak on October 13, 2023 — four days after the Peralta report was issued and three days after the board was informed. The question is whether this timing was sufficiently prompt. Four days is a relatively short period, particularly given the need for internal assessment, board deliberation, and legal consultation. However, Vantage Peak may argue that the delay — even if brief — prejudiced its ability to take protective action, or that the board's deliberation (including debate over whether to disclose at all) reflects a reluctance to be transparent rather than a good-faith process of evaluating the information.
On balance, the timing of disclosure is a secondary concern. The four-day window is defensible, and the fact that Lumos voluntarily disclosed the setback (rather than concealing it) is a significant point in the Company's favor. Nonetheless, any delay in disclosure is a factor that Vantage Peak's counsel will cite in support of the broader misrepresentation narrative, and it underscores the importance of resolving this matter promptly and cooperatively.
VI. Risk Assessment — Litigation Exposure
A. Probability of Litigation
If Lumos refuses to refund the SAFE purchase amounts or offers only a partial refund, the probability of formal litigation is high. Vantage Peak has already retained Whitfield Harte & Associates LLP, a firm with significant venture capital litigation experience, which signals a serious intent to pursue legal remedies if a negotiated resolution is not reached. The engagement of outside litigation counsel is not a step that a fund of Vantage Peak's stature takes lightly, and it should be interpreted as a credible indicator that Vantage Peak is prepared to file suit if necessary.
Moreover, if Vantage Peak initiates litigation, the co-investors — Ridgeline and Canopy Growth — would be expected to join the action or bring parallel claims. Both co-investors have the same set of facts, the same legal theories, and identical SAFEs. A joint action by all three investors would multiply Lumos's defense burden and create a unified front that would be difficult to resist.
Litigation would most likely be filed in the Delaware Court of Chancery or the Delaware Superior Court, consistent with the governing law provisions of the SAFEs. Both Lumos and the investor entities are Delaware entities, making Delaware the natural forum. The Delaware Court of Chancery, in particular, would have jurisdiction over the equitable rescission claims.
B. Potential Damages
If fraud or negligent misrepresentation were established in litigation, the primary remedy would be equitable rescission — return of the purchase amounts to the investors. Beyond the purchase amounts themselves, Lumos could face exposure to several categories of additional costs and damages:
(i) Prejudgment interest: Delaware courts routinely award prejudgment interest in rescission actions, typically at the statutory rate. On a combined exposure of $5,800,000, even a modest interest rate applied over the duration of litigation could result in a six-figure interest award.
(ii) Attorneys' fees: While Delaware follows the American Rule (each party bears its own fees), exceptions exist for cases involving bad faith or fraud. If a court were to find that Lumos acted in bad faith — either in making the initial representation or in resisting a justified refund — a fee-shifting award is possible. The SAFEs themselves do not contain a fee-shifting provision.
(iii) Consequential damages: These are unlikely in the context of a SAFE that has not converted. The investors have not suffered lost profits or other consequential harm beyond the deployment of capital. However, Vantage Peak could conceivably argue for opportunity cost damages — the return it could have earned by deploying the $3,500,000 elsewhere during the period of the dispute. Such claims are speculative and would face significant proof challenges, but they add to the litigation burden.
The maximum direct exposure is $5,800,000 (the total funded amount) plus interest and fees. Since a successful claim by the investors would ultimately require Lumos to return the funds, a voluntary refund achieves the same economic result without the incremental costs and risks of litigation.
C. Reputational Risk
Reputational risk is, in many respects, a more significant concern than the direct financial exposure. Lumos is a seed-stage company with approximately 4.1 months of post-refund runway. The Company will need to raise additional capital in the near term — potentially within the next three to four months — in order to continue operations and fund the remediation of Prism Core v2.0. Its ability to attract new investors will depend critically on its reputation in the venture ecosystem.
Litigation with Vantage Peak Ventures Fund II — a prominent venture fund with a $185 million fund size and established relationships throughout the technology investment community — would be devastating to Lumos's reputation. The venture capital ecosystem is small and interconnected; news of a fraud dispute with a lead investor would spread rapidly and would deter potential future investors from engaging with the Company. Even the existence of a dispute, if it became public through court filings or industry channels, could impair Lumos's fundraising efforts at a time when the Company can least afford such impairment.
The co-investors, Ridgeline Angel Fund and Canopy Growth Capital, are also active participants in the startup investment community. Their experience with Lumos — positive or negative — will influence the perceptions of other potential investors who may conduct reference checks or otherwise inquire about the Company's track record with its existing investor base. A cooperative and professional resolution of the current situation is far more likely to generate favorable references than a contested dispute.
D. Costs of Defense
The direct costs of defending against fraud and misrepresentation claims would be substantial and would impose a disproportionate burden on a company of Lumos's size and financial position. Litigation in the Delaware Court of Chancery or Superior Court would involve extensive discovery — including document production, depositions of key personnel (CEO Narasimhan, CTO Marsh, board member Watanabe, and potentially members of the development team), expert testimony on product development standards, and potentially review of the Company's internal communications and development records for the entire June–October 2023 period. The costs of discovery alone could easily reach six figures.
Calderwood & Harkness's current engagement for the SAFE financing round has generated fees of $67,340 against a $95,000 fee cap. A litigation matter would fall outside the scope of the current engagement and would involve substantially higher fees. Depending on the complexity and duration of the proceedings, litigation costs could range from $250,000 to $750,000 or more — an amount that Lumos simply cannot afford given its post-refund cash position of approximately $390,000 and monthly burn rate of approximately $95,000.
Beyond legal fees, litigation would consume significant management attention and time. CEO Narasimhan and CTO Marsh would be required to participate in discovery and trial preparation, diverting their attention from the critical tasks of product remediation, customer management, and fundraising. For a fourteen-person company operating on a limited runway, this management distraction would be acutely harmful.
In sum, the costs of defense — in terms of both dollars and management resources — are prohibitive given Lumos's current financial and operational position. The Company cannot afford to litigate, and a strategy premised on defense of the misrepresentation claims is not financially viable.
VII. Treatment of Atlas Fintech Syndicate
Atlas Fintech Syndicate, L.P. signed a non-binding term sheet on October 4, 2023, committing $1,000,000 to the seed financing round. However, the SAFE between Lumos and Atlas Fintech was never executed, and no funds were transferred. The term sheet expressly provides that it is non-binding and does not create any legal obligation on the part of either party to consummate the transaction.
As a result, no contractual obligation exists between Lumos and Atlas Fintech beyond the non-binding term sheet. Atlas Fintech has no claim for return of funds (because no funds were invested), no contractual rights under a SAFE (because no SAFE was executed), and no basis for a misrepresentation claim arising out of the SAFE (because no investment was made in reliance on any representation). Atlas Fintech's withdrawal from the round — whether already communicated or anticipated — requires no refund, no legal action, and no Mutual Termination & Release Agreement.
Lumos may wish, as a matter of good practice and record-keeping, to send a formal written acknowledgment to Atlas Fintech confirming the withdrawal and the termination of the non-binding term sheet. This communication should be professional, brief, and forward-looking, expressing appreciation for Atlas Fintech's interest in the Company and leaving the door open for future engagement. The communication should not reference the product setback, the Vantage Peak dispute, or the circumstances surrounding the termination of the round, as Atlas Fintech is not a party to the dispute and any unnecessary disclosure could create additional risk.
We note that the term sheet with Atlas Fintech was signed on October 4, 2023 — four days before the Peralta validation testing was completed and five days before the report was issued. The timing raises the question of whether Lumos had any obligation to inform Atlas Fintech of the product setback before proceeding to execute the SAFE. Because the SAFE was never executed and no investment was made, this question is moot as a practical matter. However, it is worth noting that if the SAFE had been executed after October 9 (the date of the Peralta report) without disclosure of the validation failure, Lumos's exposure to misrepresentation claims from Atlas Fintech would have been significantly more acute than its exposure to Vantage Peak — because in that scenario, Lumos would have had actual knowledge of the shortfall at the time of the representation. The fact that the Atlas Fintech SAFE was not executed is a fortunate outcome for the Company.
VIII. Treatment of Co-Investor SAFEs (Ridgeline and Canopy Growth)
The Ridgeline Angel Fund, L.P. SAFE ($1,200,000, executed September 22, 2023) and the Canopy Growth Capital LLC SAFE ($1,100,000, executed September 29, 2023) are on identical substantive terms as the Vantage Peak SAFE, including the same $28,000,000 post-money valuation cap, no discount, MFN provision, conversion triggers, and governing law. The same legal analysis regarding termination provisions, refund obligations, and misrepresentation exposure that applies to the Vantage Peak SAFE applies wi

PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT WORK PRODUCT

MEMORANDUM

Record

Parties

Dates

Amounts